



ISSN 3078-154X

Targeted Cancer Therapy Connect

A Journal Specialized in
Cancer Immunology and Immunotherapy

Editor-in-Chief
Eyad Elkord, PhD



SCIFINITI
PUBLISHING

Connecting Minds



OPEN ACCESS PEER-REVIEWED JOURNAL

www.scifiniti.com

Targeted Cancer Therapy Connect

A Journal Specialized in Cancer Immunology

Volume: 1, 2024

Subject Categories

Cancer Research

Immunology

Oncology

Target Audience

Cancer Immunology Connect provides a platform for researchers, clinicians, and practitioners to share their findings, discuss challenges, and explore new frontiers in the fight against cancer through immunological approaches.



Eyad Elkord

Editor-in-Chief

Department of Biological Sciences, School of Science
Xi'an Jiaotong-Liverpool University
Suzhou, China

Message from EiC

Cancer Immunology Connect is a peer-reviewed journal that aims to provide a platform for researchers and clinicians to share their latest findings and advancements in understanding the interactions between the immune system and cancer. Our goal is to foster collaboration and exchange of knowledge in this rapidly evolving area of research.

Aims and Scope

Targeted Cancer Therapy Connect is a peer-reviewed, open-access journal dedicated to advancing precision and targeted approaches in cancer treatment. The journal publishes innovative research that deepens understanding of the molecular and immunological mechanisms driving cancer progression and therapeutic response. Our goal is to accelerate the translation of scientific discoveries into effective, patient-centered cancer therapies.

Key Topics

Molecular Targets and Mechanisms – Discovery and validation of therapeutic targets; roles of oncogenes, tumor suppressors, signaling pathways, and the tumor microenvironment.

Targeted Therapeutics – Development of small-molecule inhibitors, monoclonal antibodies, antibody–drug conjugates (ADCs), peptide- and protein-based drugs, and next-generation modalities such as PROTACs.

Immunotherapy and Precision Oncology – Immune checkpoint inhibitors, bispecific antibodies, CAR-T and TCR-based therapies, vaccines, and biomarker-guided treatment strategies.

Drug Resistance and Combination Therapy – Mechanisms of resistance and rational combination regimens integrating targeted and immune-based agents.

Clinical Translation – Clinical trials of targeted agents, pharmacogenomics, predictive biomarkers, and case reports highlighting successful targeted interventions.

Technological and Methodological Advances – CRISPR, single-cell omics, proteomics, nanomedicine, and computational or AI-driven approaches for target discovery and drug development.



scifiniti.com/journals/cancer-immunology-connect



 MBZ City, Abu Dhabi, UAE

 +971 2 619 3031

 cancer.immunology@scifiniti.com